Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ocular Therapeut
(NQ:
OCUL
)
6.165
-0.105 (-1.67%)
Streaming Delayed Price
Updated: 3:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocular Therapeut
< Previous
1
2
3
4
5
6
7
Next >
Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
September 22, 2022
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...
Via
Benzinga
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Recap: Ocular Therapeutix Q2 Earnings
August 08, 2022
Ocular Therapeutix (NASDAQ:OCUL) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
August 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results
July 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
June 08, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
June 01, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
May 26, 2022
On Thursday, 94 companies set new 52-week lows.
Via
Benzinga
Expert Ratings for Ocular Therapeutix
May 10, 2022
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...
Via
Benzinga
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
May 09, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
May 03, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
April 29, 2022
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Via
Benzinga
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
April 26, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 25, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
April 17, 2022
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 14, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Recap: Ocular Therapeutix Q4 Earnings
February 28, 2022
Ocular Therapeutix (NASDAQ:OCUL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results
February 22, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360
February 11, 2022
From
Ocular Therapeutix, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.